Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials.
Jieun KangJae Seung LeeSei Won LeeJung Bok LeeYeon-Mok OhPublished in: Respiratory research (2021)
Dual therapy demonstrated benefits over monotherapy more consistently in patients with lower FEV1 than those with higher FEV1.